Pharming Group NV (PHAR) revenue breakdown
By product, RUCONEST is the largest at 85% of fiscal 2025 revenue; JOENJA grew fastest, 79% a year over 2 years.
By region, US is the largest at 96% of fiscal 2025 revenue, growing 16% a year over 7 years.
Revenue by product
Fiscal years, as Pharming Group NV reports them in its 10-K filings; fiscal 2025 total $376M.
| Products | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| RUCONEST | $227M | $252M | $318M | 85% |
| JOENJA | $18M | $45M | $58M | 15% |
Revenue by region
Fiscal years, as Pharming Group NV reports them in its 10-K filings; fiscal 2025 total $376M.
| Regions | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| US | $127M | $182M | $203M | $193M | $200M | $239M | $287M | $362M | 96% |
| Europe and RoW | $7M | $6M | $8M | $5M | $6M | $6M | $10M | $14M | 4% |
| RoW | $1M | $1M | $1M | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PHAR.
Open PHAR in InvestinglyQuestions
Where does Pharming Group NV make its money?
In fiscal 2025, by product: RUCONEST $318M, JOENJA $58M.
From Pharming Group NV's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.